Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 9:30 a.m. EST.
Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation represents an opportunity for investors and stakeholders to gain insights into the company's developments and strategic direction.
Details
News Market Reaction – ALT
The recorded move for ALT in the trading session of this news was +0.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:
| Conference: | Guggenheim SMID Cap Biotech Conference | |
| Date/Time: | Wednesday, February 5, 2025, at 9:30 a.m. EST | |
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.